by Samuel White | 11th September 2023
For brain tumours, X-ray radiotherapy is used to reduce tumour bulk, treat inoperable tumours or secondary brain tumours. However, quality of life remains affected, and metastases and relapses still occur. Other, more targeted forms of radiotherapy are now being...
by Samuel White | 11th September 2023
Semantic segmentation of brain structures from medical images, in particular Magnetic Resonance Imaging (MRI), plays an important role in many neuroimaging applications. Deep learning based segmentation algorithms are now achieving state-of-the-art segmentation...
by Samuel White | 11th September 2023
Most lung cancer deaths result from ineffective treatment of late-stage disease. Currently, there is no satisfactory way to identify patients that will not respond to standard-of-care treatments. Positron emission tomography (PET) imaging offers a potential solution...
by Samuel White | 11th September 2023
Background MRI is an incredibly successful medical imaging modality, with 3.8 million scans acquired in the NHS in the year preceding March 2022. However, MR imaging in young children is difficult. Scanners are built to fit the largest adults, resulting in suboptimal...
by Samuel White | 11th September 2023
Huntington’s Disease (HD) is an inherited neurodegenerative disorder caused by a CAG (codon that codes for amino acid glutamine) repeat expansion in the huntingtin gene (HTT). The prevalence of HD varies by ethnic origin and occurs mainly in Caucasian populations....
by Samuel White | 11th September 2023
Half of patients with melanoma, the most lethal skin cancer, and a large proportion of patients with aggressive breast cancers such as the triple negative subtypes, do not respond to currently-available antibody immunotherapies. Existing anti-cancer antibody-based...
by Samuel White | 11th September 2023
Early-onset epilepsy is associated with poor developmental outcomes. Limited evidence suggests that specific maternal characteristics are associated with early-onset epilepsy, and that certain features of epilepsy predict diagnosis of neurodevelopmental conditions,...
by Samuel White | 11th September 2023
Background: Depression and anxiety rates are rising. These debilitating disorders impact all aspects of life. Psychological therapies are more widely available than ever, but only ~50% of those treated recover. We must find ways to get people into the right form of...
by Samuel White | 11th September 2023
Background: Pancreatic cancer is one of the most lethal cancers in humans. There is a high unmet medical need to develop new therapies for the treatment of this disease. Drugs which engage the immune system (immunotherapies) have shown a survival benefit in lung...
by Samuel White | 11th September 2023
Proteolysis-targeting chimeras (PROTACs) are an emerging new therapeutic class of drugs with the potential to open “drug target space” not accessible to conventional small molecule drugs. PROTACs have potential applications in many diseases, with their potential as...
by Samuel White | 11th September 2023
An area of untapped potential in drug development is the so-called undruggable space. Undruggable proteins are defined as those unable to be pharmacologically targeted via conventional small molecule drugs. In recent years, new modalities have arisen that have the...
by Samuel White | 11th September 2023
Background: Synapse formation and maturation is arguably one of the most important steps to ensure the function of neural circuits during development. At the same time, synaptic defects and loss of synaptic functionality are common features across many...
